Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.51 |
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | FES | P07332 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645960 | 0.95 | NPC1 (0.46) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL8234095 | 0.95 | NPC1 (0.55) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL645446 | 0.95 | ABCB1 (0.44) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL647961 | 0.94 | NPC1 (0.45) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL648285 | 0.93 | KMT2A (0.46) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL645754 | 0.91 | HPGDS (0.40) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL10151395 | 0.89 | RAB9A (0.41) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL645416 | 0.89 | NPC1 (0.44) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL647662 | 0.89 | RAB9A (0.46) | NPC1RAB9ATP53MITFGAA | |
| SCHEMBL645996 | 0.89 | NPC1 (0.38) | NPC1RAB9ATP53MITFGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614321-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2001476-A2 | BENZOIMIDAZOLYL-PARAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2007109362-A2 | BENZOIMIDAZOLYL-PARAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR5, NLRP3 | NPC1 852/4885RAB9A 3009/4885TP53 757/4885 |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | IL5, CXCR5, NLRP3 | NPC1 852/4885RAB9A 3009/4885TP53 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.